NEW YORK (GenomeWeb News) – Interleukin Genetics reported yesterday that its first-quarter revenues declined 30 percent and its net loss rose 32 percent, as its consumer product sales and contract research revenue fell.

The Waltham, Mass.-based genetic test maker brought in total revenues of $1.9 million, down from $2.7 million. Its consumer products sales fell to $1.5 million from $2 million year over year, while its contract research revenues were $203,687 versus $537,013 the year before. The firm's genetic testing service revenue increased to $137,511 from $101,752.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.